Are NTD programs in Anambra State, Nigeria, adopting and implementing prevention measures for COVID-19 in their drug delivery activities? What adaptations are required by staff and volunteers to adopt these measures? What are the barriers to doing so? What are the incremental costs associated with conducting MDA during a global pandemic?
Evaluating the adoption of COVID-19 prevention measures during mass drug administration in Anambra State, Nigeria
Sample size of 40 includes up to 10 MoH personnel and 30 CDDs that will take part in qualitative interviews. Implementing partner staff and community members may also be interviewed. Rapid observations of MDA using quantitative checklists will also be conducted to assess CDD adherence to revised SOPs.